Principal components analysis of agitation outcomes in Alzheimer's disease

For the CitAD Research Group

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: We developed a composite measure of agitation as a secondary outcome of change over time in the Citalopram for Agitation in Alzheimer's disease study (CitAD). CitAD demonstrated a positive effect of citalopram on agitation on the Neurobehavioral Rating Scale agitation subscale (NBRS-A). CitAD included additional agitation measures such as the Cohen-Mansfield Agitation Inventory and the Neuropsychiatric Inventory. Methods: We performed principal components analyses on change in individual item of these scales for the same, original CitAD subjects. Results: The first principal component accounted for 12.6% of the observed variance and was composed of items that appear to reflect agitation. The effect size for citalopram calculated using this component was 0.53 (95% CI 0.22-0.83) versus 0.32 for the NBRS-A (95% CI 0.01-0.62). Conclusions: Results suggest that a composite measure of change in agitation might be more sensitive than change in a single primary agitation measure.

Original languageEnglish (US)
Pages (from-to)4-7
Number of pages4
JournalJournal of Psychiatric Research
StatePublished - Aug 1 2016


  • Agitation
  • Alzheimer's disease
  • Principal component analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Principal components analysis of agitation outcomes in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this